Search

Memorial Sloan Kettering Cancer Center (MSK) is pleased to announce TIME has named two MSK physician-scientists, Andrea Cercek, MD, and Vinod Balachandran, MD, to the 2025 TIME100 Health, a list of the 100 most influential individuals in health.

… Thursday, May 8, 2025 Memorial Sloan Kettering Cancer Center (MSK) is pleased to announce TIME has named two MSK physician-scientists, Andrea Cercek, MD , and Vinod Balachandran, MD , to the 2025 TIME100 Health , a list of the 100 most influential individuals in health. Dr. Cercek is recognized for her

Learn about how MSK’s new Lobular Breast Cancer Program is working to improve outcomes for people with invasive lobular breast cancer and other types of LBC.

… Thursday, October 2, 2025 Because lobular breast cancer (LBC) is a type of breast cancer that can be difficult to detect and challenging to treat, it is the focus of a special program at Memorial Sloan Kettering Cancer Center (MSK). Also called invasive lobular carcinoma, it is the second most common

Radiation is a feasible option for patients with squamous cell carcinoma of the anterior nasal cavity mucosa who refuse rhinectomy, according to our recent research.

… Friday, June 7, 2019 Our findings demonstrate that a non-operative approach with high-dose radiotherapy and concurrent chemoradiotherapy can result in favorable outcomes. Marc A. Cohen Associate Chief Medical Officer, Access and Patient Flow; Surgical Director, Pituitary and Skull Base Tumor Center Radiation

Hear from cervical cancer survivor Susan Shaw about how she joined the Empire Dragon Boat Team three years ago and is in the best shape of her life.

… Tuesday, August 21, 2018 Summary This story originally appeared in Bridges, MSK’s newsletter for cancer survivors. Bridges offers a forum in which patients and their families can share stories of inspiration and hope, and of the challenges that can accompany a cancer journey. Learn more about how to

Learn how a young woman diagnosed with stage 4 non-small cell lung cancer had many treatment options because she came to MSK first.

… Monday, November 25, 2024 The diagnosis was earth-shattering, especially for someone who had never smoked..  Jhalene Mundin, a 35-year-old mother of two young children, was told in July 2023 that she had stage 4 (metastatic) non-small cell  lung cancer .  It had spread beyond her lungs and was considered

Descubra cómo una mujer joven diagnosticada con cáncer pulmonar de células no pequeñas en estadio 4 tuvo muchas opciones de tratamiento porque acudió primero a MSK.

… Monday, November 25, 2024 El diagnóstico fue devastador, especialmente para alguien que nunca había fumado. A Jhalene Mundin, de 35 años y madre de dos niños pequeños, le informaron en julio de 2023 que tenía  cáncer pulmonar de células no pequeñas en estadio 4 (metastásico) .  Se había diseminado más

Patients with early-stage, node-positive breast cancer whose nodes are pathologically tumor-free after neoadjuvant chemotherapy may safely skip post-mastectomy nodal irradiation without increasing the risk of invasive breast cancer recurrence or death, according to results from a clinical trial published recently in NEJM.

… Monday, August 18, 2025 Patients with early-stage, node-positive breast cancer whose nodes are pathologically tumor-free (ypN0) after neoadjuvant chemotherapy may safely skip post-mastectomy nodal irradiation without increasing the risk of invasive breast cancer recurrence or death, according to results

By looking at how DNA is packaged in cells, scientists are teasing apart a long-standing conundrum about the immune response to cancer.

… Wednesday, May 17, 2017 Summary Immunotherapy as an approach to cancer treatment involves prodding immune cells to see cancer as dangerous and attack it. Why some immune cells seem resistant to this prodding is a question that researchers are actively trying to understand. By looking at how DNA is packaged

Memorial Sloan Kettering Cancer Center has appointed Gilles Salles, MD, PhD, Chief of the Lymphoma Service, Division of Hematologic Malignancies.

… Friday, November 12, 2021 Memorial Sloan Kettering Cancer Center (MSK) has appointed Gilles Salles, MD, PhD , as Chief of the Lymphoma Service, Division of Hematologic Malignancies. He succeeds Anas Younes, MD. Dr. Salles received his MD and PhD from the Université Claude Bernard Lyon and completed a

High-risk neuroblastoma cells harbor distinguishing molecular signatures, according to recent research.

… Friday, August 2, 2019 High-risk neuroblastoma cells harbor distinguishing molecular signatures, according to research that physician-scientists at Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine published recently in the journal Neoplasia. These unique characteristics distinguish neuroblastoma